Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Argenx SE
Biogen Inc
Cellenkos Inc
GeNeuro SA
HanAll Biopharma Co Ltd
Immupharma Plc
Johnson & Johnson
Octapharma AG
Pfizer Inc
Sanofi
Takeda Pharmaceutical Co Ltd
UCB SA